Arena Pharmaceuticals Inc: (NASD: ARNA)

$7.51

0.01 (0.13%)

Volume 5,392,820

Jun 18 04:00 PM ET

Zacks Rank: 3-Hold

 
 
#3
 
 

Overview Quote

Get Overview Quote for:

Stock Activity

Day Low - High 7.40 - 7.57
52wk Low - High 6.95 - 13.50
Previous Close 7.50
Avg. Volume 5,541,080
Industry MED-BIOMED/GENE
Market Cap 1.63 B
Div - Yield 0.00 - 0.00
Beta 0.18
P/E (F1) 0.00
Current Year Est. -0.12
Quarterly Earnings ESP NA

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

3

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Neutral

Zacks Industry Rank

105 out of 265

Equity Research Report

Updated as of 06/12/2013

PREMIUM

( = Change in last 30 days)

Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial

Key Earnings Data

P/E (F1) NA
PEG Ratio NA
Current Year Est. -0.12
Current Quarter Estimate 0.12
Most Accurate Estimate NA
Earnings ESP NA
Next Earnings Report Date 08-08-2013
EPS Last Year -0.38
Expected Earnings Growth NA

Company Description

Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

NYSE data is at least 20 minutes delayed.

NASDAQ data is at least 15 minutes delayed.

Interactive Java Charting | Fundamental Charts

Introducing Zacks Whisper Trader

Turn Earnings Surprises into quick profits.

 

ARNA Chart by YCharts

Earnings Estimates

Current Qtr
(06/2013)
Next Qtr
(09/2013)
Current Year
(12/2013)
Next Year
(12/2014)
Average Estimate 0.12 -0.05 -0.12 -0.24
Number of Estimates 6 5 7 6
Low Estimate -0.11 -0.12 -0.15 -0.39
High Estimate 0.19 0.17 -0.08 NA
Year Ago EPS -0.12 -0.07 -0.42 -0.12
EPS Growth 202.78% 22.86% 72.11% -104.88%

Average Earnings Estimates for ARNA

EPS Growth for ARNA

Industry Analysis

Name Symbol Previous Close Zacks Rank Zacks Recommendation
ARENA PHARMA ARNA 7.50
AETERNA ZENTARS AEZS 1.90
BIOGEN IDEC INC BIIB 207.75
MYRIAD GENETICS MYGN 26.62
PROTALIX BIOTHR PLX 5.04
ADDEX THERA LTD ADDXF 3.95
AFFYMAX INC AFFY 1.09
ALEXION PHARMA ALXN 91.32
ALNYLAM PHARMA ALNY 29.69
ANTHERA PHARMA ANTH 0.57

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Financials

EPS TTM -0.38
Sales 28
Net Income -78
Price/Earnings NA
Price/Book 20.28
Price/Cash Flow NA
Price/Sales 58.81

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.